ARTICLE IN PRESS
Journal of Theoretical Biology 237 (2005) 117–132
www.elsevier.com/locate/yjtbi
A mathematical model of hematopoiesis—I. Periodic chronic
myelogenous leukemia
Caroline Colijna, Michael C. Mackeyb,
a
Department of Mathematics and Centre for Nonlinear Dynamics, McGill University, 3655 Promenade Sir William Osler, Montreal, Que.,
Canada H3G 1Y6
b
Departments of Physiology, Physics and Mathematics and Centre for Nonlinear Dynamics, McGill University, 3655 Promenade Sir William Osler,
Montreal, Que., Canada, H3G 1Y6
Received 16 December 2004; received in revised form 22 March 2005; accepted 30 March 2005
Available online 21 June 2005
Abstract
Periodic chronic myelogenous leukemia (PCML) is an interesting dynamical disease of the hematopoietic system in which
oscillating levels of circulating leukocytes, platelets and/or reticulocytes are observed. Typically all of these three differentiated cell
types have the same oscillation period, but the relation of the oscillation mean and amplitude to the normal levels is variable. Given
the appearance of the abnormal Philadelphia chromosome in all of the nucleated progeny of the hematopoietic stem cells (HSCs),
the most parsimonious conclusion is that chronic myelogenous leukemia, and its periodic variant, arise from derangements partially
involving the dynamics of the stem cells. Here, we have synthesized several previous mathematical models of HSC dynamics, and
models for the regulation of neutrophils, platelets and erythrocytes into a comprehensive model for the regulation of the
hematopoietic system. Based on estimates of parameters for a typical normal human, we have systematically explored the changes in
some of these parameters necessary to account for the quantitative data on leukocyte, platelet and reticulocyte cycling in 11 patients
with PCML. Our results indicate that the critical model parameter changes required to simulate the PCML patient data are an
increase in the amplification in the leukocyte line, an increase in the differentiation rate from the stem cell compartment into the
leukocyte line, and the rate of apoptosis in the stem cell compartment. Our model system is particularly sensitive to changes in stem
cell apoptosis rates, suggesting that changes in the numbers of proliferating stem cells may be important in generating PCML.
r 2005 Elsevier Ltd. All rights reserved.
Keywords: Leukemia; Mathematical model
1. Introduction
All blood cells arise from a common origin in the
bone marrow, the hematopoietic stem cells (HSCs).
These stem cells can differentiate into one of three
major cell lines: the leukocytes, the platelets, and the
erythrocytes. The exact details of how the numbers
of circulating cells of each type are regulated remain
Corresponding author. Tel.: +1 514 398 4336;
fax: +1 514 398 7452.
E-mail addresses: ccolijn@cnd.mcgill.ca (C. Colijn),
mackey@cnd.mcgill.ca (M.C. Mackey).
0022-5193/$ - see front matter r 2005 Elsevier Ltd. All rights reserved.
doi:10.1016/j.jtbi.2005.03.033
somewhat obscure, though the broad outlines are
clear.
For the red blood cells, the cytokine erythropoietin
(EPO) mediates a negative feedback loop that helps to
regulate erythrocyte production (Adamson, 1974; Silva
et al., 1996). A decrease in numbers of circulating
erythrocytes leads to a decrease in tissue pO2 levels,
which in turns triggers a production and release of EPO
by renal macula cells. This elevation of EPO increases
the net production of primitive erythroid precursors, and finally an increase in the numbers of
circulating erythrocytes takes place some days later.
In the production of white blood cells, granulocyte
ARTICLE IN PRESS
118
C. Colijn, M.C. Mackey / Journal of Theoretical Biology 237 (2005) 117–132
colony-stimulating factor (G-CSF) has been demonstrated to be very important and it too mediates a
negative feedback loop (Price et al., 1996). As for the
erythrocytes and leukocytes, the production of platelets
involves a negative feedback loop, related to the
production and maturation of megakaryocytes. These
are platelet precursor cells that give rise to 1000–5000
platelets each (Beutler et al., 1995). Thrombopoietin
(TPO), which is known to be involved in platelet
production, mediates this negative feedback and TPO
has been shown to have effects on other cell lines
as well (Ratajczak et al., 1997; Tanimukai et al., 1997),
which could imply that the three lines are not fully
independent.
The regulation of the HSC population is also of
importance. Previous mathematical models of HSC
dynamics have been based on a G 0 cell cycle model,
and thus considered actively proliferating stem cells and
quiescent, non-proliferating cells in the so-called G 0
phase (Mackey, 1978, 1979a, 2000; Fowler and Mackey,
2002; Pujo-Menjouet et al., 2001). There is typically a
delay in mathematical models of the stem cells, reflecting
the non-zero time that it takes the cells to complete the
proliferative phase of the cell cycle which includes DNA
synthesis, mitosis, and cytokinesis. However, the parameters determining the rate of proliferation in the stem
cell compartment, which depends ultimately on the
current number of stem cells, are not well-known (PujoMenjouet et al., 2001; Ogawa, 1993; Lemishka et al.,
1986). Since stem cell oscillations are thought to drive
oscillations in several periodic hematological diseases
(Haurie et al., 1998), developing a better knowledge of
stem cell dynamics is important.
There is significant autonomy between the three cell
lines, as evidenced by their distinct responses to varying
circulating cell numbers in each line; i.e. to distinct
demands for production. Several hematological diseases
provide motivation for the mathematical study of
hematopoietic regulation, as well as providing the
opportunity to study early hematopoietic regulation
and its effects on the relationships between the cell lines
(Haurie et al., 1998). These disorders include (but are
not limited to) cyclical neutropenia (CN), periodic
chronic myelogenous leukemia (PCML), cyclical thrombocytopenia, and periodic hemolytic anemia. The first
two involve oscillations in all circulating hematological
cells with the same period. The regulatory mechanisms
in early hematopoiesis are not as well understood as the
peripheral hematopoietic regulatory elements. Thus,
periodic hematological disorders in which oscillations
occur in more than one cell line are of considerable
interest since the most parsimonious explanation of
oscillatory pathologies involving more than one cell type
is that they arise in the HSC. Of particular interest here
will be periodic CML, in which oscillations occur
primarily in the leukocytes, but may also occur in the
platelets and in some cases the reticulocytes (Fortin and
Mackey, 1999).
Leukemia is a disease of the blood and bone marrow,
characterized by large and apparently uncontrolled
accumulation of blood cells. Myelogenous leukemia
involves the myelocytes, which are granular leukocyte
precursors. In acute leukemia, the disease progresses
rapidly, and produces large numbers of immature nonfunctioning white blood cells. In chronic forms of
leukemia, the cells produced are initially more functional.
CML is associated with a chromosomal abnormality,
known as the Philadelphia chromosome, that occurs in
all cell lineages in about 90% of cases. This abnormality
consists of a transposition of parts of chromosomes 9
and 22, and results in the formation of the Bcr–Abl
fusion protein (ODwyer et al., 2000). This protein is
thought to be responsible for the dysfunctional regulation of myelocyte growth and other features of CML
(Melo, 1996). (See Grignani (1985) for more detail about
CML.)
In periodic chronic myelogenous leukemia (PCML)
the leukocyte count varies periodically, typically between
values of 30 and 200 109 cells L1 . This is far above the
normal value of 6 109 cells L1 . The variation occurs
with a period in the range of 40–80 days, which is very
long in comparison with the maturation and lifespan of
the stem cells and the leukocytes. In addition, oscillations
may occur in the platelets and occasionally also in the
reticulocytes, and in these cases the platelet and
reticulocyte periods are the same as the leukocyte periods
(Henderson et al., 1996; Fortin and Mackey, 1999). It
has been argued that this, in addition to the occurrence
of the Philadelphia chromosome in all differentiated
lineages, is indicative of the stem cell origins of PCML
(Fortin and Mackey, 1999).
In both PCML and CN, the hypothesis that oscillations originate in the stem cells is related to the fact that
oscillations occur in different lines. However, in many
earlier mathematical models, only one cell line, or one
line coupled to the stem cells, is represented. In this
context, it is not possible to examine the effects of a
destabilization in one line or in the stem cell compartment on whole system. For example, while PujoMenjouet et al. (2001) explored how long-period
oscillations (as seen in PCML) could arise within the
context of a G 0 stem cell model, the stem cell model
alone could not predict whether the leukocytes and
platelets would oscillate at the levels observed in PCML.
Similarly, Bernard et al. (2003) were able to duplicate
various features of CN with an integrated mathematical
model of the HSC and peripheral neutrophil control.
However, since their model did not include platelet and
erythrocyte regulation it is unknown if their simulated
neutropenic conditions would be consistent with observed platelet and erythrocyte data in CN.
ARTICLE IN PRESS
119
C. Colijn, M.C. Mackey / Journal of Theoretical Biology 237 (2005) 117–132
This paper presents a model framework within which
these questions can be addressed. We utilize a G 0 type
model for the stem cell compartment, based on the work
of Pujo-Menjouet et al. (2001), and couple it to a
leukocyte model based on that of Bernard et al. (2003),
as well as to two simplified models representing
peripheral platelet and erythrocyte regulation. In Section 2.1, the model is described, including the various
feedback and control functions that capture the essence
of the control exercised by G-CSF, EPO and TPO.
Section 2.2 deals with the parameter estimation for the
model in the normal (non-pathophysiological) case. In
Section 3, the published PCML data with which the
model is compared are briefly described. This is followed
in Section 4 with a description of the techniques used to
fit the parameters in the model to the PCML data, and
the results of the fitting approaches along with their
interpretation.
2. A model of the hematopoietic system
τS QτS
a = τS
a=0
Q(t)
s (t,a)
γS
κN
κR
AP
AR
AN
κP
τPM
τNM
τRM
N(T)
τPS
τRS
2.1. Model formulation
In previous work leukocyte (Hearn et al., 1998;
Haurie and Mackey, 2000; Bernard et al., 2003),
erythrocyte (Mackey, 1979b; Bélair et al., 1995; Mahaffy
et al., 1998a) and platelet (Bélair and Mackey, 1987;
Santillan et al., 2000) dynamics have been modelled
separately, with the goal of building quantitative
understanding of cellular production within the context
of periodic hematological disorders. The goal of the
present work is to link these models together, connecting
models for the three distinct cell lines to a mathematical
model of the stem cell population (Mackey, 1978). The
present model thus has four distinct compartments
representing the HSC and the circulating leukocytes,
platelets and erythrocytes. The stem cells are pluripotential and self-renewing, and can differentiate into the
leukocyte, erythrocyte or platelet lines. Alternatively,
the stem cells may re-enter the proliferative phase of the
stem cell compartment. The stem cell and leukocyte
compartments are modelled using the stem cell model
connected to a neutrophil population as in Bernard et al.
(2003). The platelet and erythrocyte compartments are
simplified approximations of earlier modelling efforts.
The full model is illustrated in Fig. 1.
The pluripotential, non-proliferating stem cells are
denoted by Q (in units of 106 cells kg1 , see Fig. 1). The
circulating leukocytes, erythrocytes and platelets are
denoted N (units 109 cells kg1 ), R (units 1011 cells kg1 )
and P (units 1010 cells kg1 ), respectively. The rates of
differentiation into these three lines are given by kN ðNÞ,
kR ðRÞ and kP ðPÞ, respectively. These differentiation
rates have units of days1 . The fact that these rates
each depend on the numbers of circulating cells of the
γN
γP
γR
P(T)
R(T)
Fig. 1. A cartoon representation of the full model including the HSC
and the three differentiated cell lines. See the text for full details as well
as the notation.
relevant type encapsulates the feedback between the
circulating cell numbers and the production; the feedback is always negative so when the number of
circulating mature cells of a given line falls, the relevant
differentiation rate k has a corresponding compensatory
increase. More discussion of the forms of kN ðNÞ, kR ðRÞ
and kP ðPÞ will follow.
With reference to Fig. 1, first consider the stem cell
portion of the model. There are two ways that the stem
cells can exit the non-proliferating compartment: they
can either re-enter the proliferating phase at a rate bðQÞ
(units of days1 ), or they can differentiate into any of
the three cell lines, at rates kN ðNÞ, kR ðRÞ and kP ðPÞ for
the leukocytes, erythrocytes and platelets respectively.
After re-entering the proliferating phase, the cells divide,
taking a time tS (units of days) to do so.
The production of Q, where Q represents the density
of non-proliferating stem cells, is given by the flux of
stem cells entering the proliferative phase, multiplied
by two to account for cell division, and delayed by the
time tS that it takes them to multiply. However, the
number of cells leaving the proliferating compartment
is not simply twice the number that entered it a time tS
ago, because during proliferation, there may be loss
ARTICLE IN PRESS
120
C. Colijn, M.C. Mackey / Journal of Theoretical Biology 237 (2005) 117–132
through cell death. We represent this loss as occurring
at a rate gS (units of days1 ) over the time period
tS . Thus, the number of non-proliferating stem
cells entering per unit time (and augmenting Q) is
2egS tS bðQðt tS ÞÞQðt tS Þ. (In this paper, we always
use the notation QtS Qðt tS Þ.) The loss from the
non-proliferating compartment is given by the sum of
the terms representing differentiation into the three cell
lines, plus the loss due to the cells re-entering the
proliferative phase. Thus, the differential delay equation
governing Q is
dQ
¼ bðQÞQ ðkN þ kR þ kP ÞQ
dt
þ 2egS tS bðQðt tS ÞÞQðt tS Þ.
ð1Þ
There are three more differential delay equations in
the model, each representing one cell line. These three
models for peripheral control share some common
features and display some differences. In each cell line
there is an amplification stage representing many stages
of cell division (typically 12–18, depending on the cell
line). The dimensionless amplification parameters are
AN , AR and AP . Following completion of amplification
through cell division, the cells traverse a maturation
compartment (duration in days denoted by tiM ), where
i ¼ N; R; P) and then enter the circulation. While the
leukocytes die at a constant rate gN (units of days1 ), the
platelets and erythrocytes enter an ‘age-structured’
compartment where they persist over times tRS and
tPS , respectively, and are primarily lost to senescence.
However, there are also well documented random losses
of platelets and erythrocytes represented by gR and gP
(again units of days1 ).
Specifically considering the leukocytes, after amplification and maturation they enter the circulating
leukocyte compartment (denoted by N). They are
randomly lost at a rate gN . The time for maturation is
denoted by tN , and the equation governing the
leukocytes is then, as in Bernard et al. (2003)
dN
¼ gN N þ AN kN ðN tN ÞQtN .
dt
(2)
The platelet and erythrocyte dynamics are somewhat
more complex. Indeed, in previous work (Mahaffy et al.,
1998b; Santillan et al., 2000), age-structured models
were used to represent their dynamics in the bone
marrow and the loss via senescence of circulating
erythrocytes and platelets. In the present model we
will replace the age distribution simply with discrete
delays in the erythrocyte and platelet lines (Mackey,
1996). The equations for the erythrocyte and platelet
dynamics are
dR
¼ gR R þ AR fkR ðRtRM ÞQtRM
dt
egR tRS kR ðRtRM þtRS ÞQtRM þtRS g
ð3Þ
and
dP
¼ gP P þ AP fkP ðPtPM ÞQtPM
dt
egP tPS kP ðPtPM þtPS ÞQtPM þtPS g.
ð4Þ
In Eq. (3), the term gR R reflects a random loss of
erythrocytes at rate gR . The positive term in Eq. (3)
represents the amplification of the cells entering the
erythrocyte line from the stem cell compartment, minus
the loss that accrues in the age-structured compartment
(represented by the lower box in the erythrocyte line; see
Fig. 1) over the time tRS . Eq. (4) for the platelet
compartment has exactly the same structure as Eq. (3),
and all the terms in Eq. (4) are analogous to those in
Eq. (3).
The lifetime tRS ¼ 120 days is very long, and
consequently oscillations in the HSC or the leukocyte
and platelet lines may not be transmitted visibly to the
erythrocyte line due to the damping of the long timescale. However, oscillations may be visible in the
erythrocyte precursors (the reticulocytes), and for this
reason, we have divided the erythrocyte compartment
into two sub-compartments for the purposes of comparing model simulations with existing reticulocyte data.
Eq. (3) is thus replaced by two equations
dL
¼ gR L þ AR fkR ðRtRM ÞQtRM
dt
egR tret kR ðRtRM þtret ÞQtRM þtret g
ð5Þ
and
dR
¼ gR R þ AR fegR tret kR ðRtRM þtret ÞQtRM þtret
dt
egR tsum kR ðRtsum ÞQtsum g,
ð6Þ
L now represents the reticulocytes, and R still represents
the erythrocytes, which are simply the ‘later’ component
of the simplified age-structured box of Fig. 1. The delay
time tsum is the total time spent after maturation, tsum ¼
120 days.
It remains to discuss the forms of the feedback
functions kN , kP and kR , as well as the rate bðQÞ at
which the stem cells return to the proliferative phase. In
Bernard et al. (2003), the re-entry rate to the proliferative phase was given as
bðQÞ ¼ k0
ys2
.
ys2 þ Qs
(7)
The form of this equation is very common in enzyme
kinetic relations (see the discussion in Bernard et al.
(2003)), and offers a good match to existing data as well
as providing convenient analytical properties. We will
use the parameters given in Bernard et al. (2003) for this
function (see Table 2).
ARTICLE IN PRESS
C. Colijn, M.C. Mackey / Journal of Theoretical Biology 237 (2005) 117–132
For the leukocyte feedback function kN , we use the
same function as was used in Bernard et al. (2003)
kN ðNÞ ¼ f 0
yn1
.
yn1 þ N n
(8)
121
which is exactly analogous to Eq. (9). By the same
reasoning, we use
kR ðRÞ / E /
1
1 þ K r Rm
(12)
and write
This function is derived from the assumption that the
differentiation rate is proportional to the number of
bound G-CSF receptors on the cells. While the
concentration of G-CSF changes with time, for a given
leukocyte concentration, the G-CSF concentration
reaches equilibrium on a time-scale of hours, whereas
the time-scale of interest in our study of periodic
hematological disorders is on the order of weeks. We
therefore make the additional assumption that the
G-CSF concentration changes rapidly enough that it
reaches equilibrium with respect to the number of
circulating white blood cells. This is what allows us to
write the rate of differentiation of the stem cells into the
leukocyte line as a function of N rather than as a
function of the G-CSF concentration; see Bernard et al.
(2003) for a derivation of Eq. (8).
Megakaryocytes are platelet precursors, each of which
produces, on average, 1000–5000 platelets (Beutler et al.,
1995). In Santillan et al. (2000) the authors assumed that
the number of megakaryocytes of age 0, entering from
the stem cell compartment, was simply proportional to
the concentration of TPO. In our model, we preserve the
approximation that the differentiation is proportional to
the thrombopoiesis concentration, but assume, as in the
case of G-CSF, that the TPO is in dynamic equilibrium
with the platelet numbers, and hence that dT=dt ¼ 0,
where T is the concentration of TPO. From Santillan
et al. (2000),
dT
a
¼
kT,
dt
1 þ KPr
kR ðRÞ ¼
1
1 þ K p Pr
dQ
¼ bðQÞQ ðkN þ kR þ kP ÞQ þ 2egS tS bðQtS ÞQtS ,
dt
dN
¼ gN N þ AN kN ðN tN ÞQtN ,
dt
dL
¼ gR L þ AR fkR ðRtRM ÞQtRM
dt
egR tret kR ðRtRM þtret ÞQtRM þtret g,
dR
¼ gR R þ AR fegR tret kR ðRtRM þtret ÞQtRM þtret
dt
egR tsum kR ðRtsum ÞQtsum g,
dP
¼ gP P þ AP fkP ðPtPM ÞQtPM
dt
egP tPS kP ðPtPM þtPS ÞQtPM þtPS g,
bðQÞ ¼ k0
k̄p
.
1 þ K p Pr
(11)
The rate kR of differentiation into the erythrocyte line is
modelled similarly. Indeed, in Mahaffy et al. (1998a), it
was assumed that the number of new precursor cells
entering the erythrocyte line was linearly proportional to
the concentration of EPO. There, the authors develop
the equation
dE
a
¼
kE,
dt
1 þ KRm
ys2
,
ys2 þ Qs
kN ðNÞ ¼ f 0
yn1
,
yn1 þ N n
kP ðPÞ ¼
k̄p
,
1 þ K p Pr
kR ðRÞ ¼
k̄r
.
1 þ K r Rm
(15)
For reference, the delays in the system, and the time
values composing them, are listed in Table 1.
and can write
kP ðPÞ ¼
ð14Þ
where
(9)
(10)
(13)
In summary, the equations comprising the model are
so we have
kP ðPÞ / T /
k̄r
.
1 þ K r Rm
Table 1
Delays in the model
Delay
Description
tS
tN
tRM
tret
tRS
tsum
tPM
tPS
Stem cell proliferation time
Leukocyte maturation time
Erythrocyte maturation time
Reticulocyte maturation time
Erythrocyte aging time to senescence
tRM þ tret þ tRS
Platelet maturation time
Platelet aging time to senescence
ARTICLE IN PRESS
122
C. Colijn, M.C. Mackey / Journal of Theoretical Biology 237 (2005) 117–132
2.2. Parameter estimation
Throughout this discussion, the subscript indicates a
steady-state value. The steady-state values are obtained
(and related to other parameters) by setting the rates of
change in Eq. (14) to zero: Q_ ¼ N_ ¼ L_ ¼ R_ ¼ P_ 0.
2.2.1. The stem cell compartment
The HSC parameters are the death rate gS in the
proliferating phase, the time tS that cells spend in the
proliferative phase, the parameters k0 , ys and s
occurring in the Hill function bðQÞ, and the size of
the non-proliferative HSC compartment Q at steady
state, Q .
The value of Q is derived from various data.
Abkowitz et al. (1988) give a value of 8 stem cells per
105 nucleated bone marrow cells in cats, while in mice it
is estimated that there are 1–50 stem cells per 105
nucleated bone marrow cells (Boggs et al., 1982;
Micklem et al., 1987). Since there are approximately
1:4 1010 nucleated bone marrow cells per kg of body
mass in mice, this would imply that there are between
1:4 105 and 7 106 HSC per kg body mass in mice, or
1:1 106 stem cells per kg body mass in cats. We have
adopted the latter value so Q ¼ 1:1 106 stem cells per
kg body mass.
Mackey (2000) has estimated in the mouse that
gS 2 ð0:069; 0:228Þ day1 , that the steady-state rate of
re-entry from the non-proliferative phase to the
proliferative phase is bðQ Þ 2 ð0:020; 0:053Þ day1 , tS 2
ð1:41; 4:25Þ days, and that the steady-state rate of
differentiation into all cell lines from Q is between
0.010 and 0:024 day1 . The duration of the proliferative
phase of the HSC cell cycle has been estimated as tS ¼
2:8 days by Abkowitz et al. (1988) in the cat, and
between 1.4 and 4.3 days by Mackey (2000) in the
mouse.
Bernard et al. (2003) give the rate of apoptosis in the
stem cell compartment gS ¼ 0:01–0:2 days1 . In their
discussion of long-period oscillation in a G 0 stem cell
model, Pujo-Menjouet et al. (2001) give 0:18 days1 , and
in Mackey (2000) the range for gS is given as
0.07–0:23 days1 . We began our simulations with
gS ¼ 0:18. Abkowitz et al. (1988) estimated the mean
proliferation rate of HSCs in mice to be bðQ Þ ¼
0:06 days1 which, in combination with the other Hill
function parameters given in Bernard et al. (2003), gives
y2 ¼ 0:5 ð106 Þ cell kg1 and k0 ¼ 3:0 days1 . These
parameters are taken from a variety of experiments
(Lyons, 1999; Oostendorp, 1995), in conjunction with
fitting a visual inspection of the Bernard et al. (2003)
model to experimental data.
The parameter s may be interpreted as the number of
ligand molecules that are required in the activation of a
receptor site, which in the case of HSCs is not well
understood. Bernard et al. (2003) estimate that the value
of s is between 2 and 4. Based on our results and the
discussion of oscillations in the stem cell model analysed
by Pujo-Menjouet et al. (2001), we have used s ¼ 4.
2.2.2. The leukocyte compartment
For the leukocyte control dynamics, we need to
estimate the stationary state (mean) leukocyte count,
N , as well as the loss rate gN , the leukocyte maturation
time tN and the Hill function parameters f 0 , y1 and n.
The loss rate of circulating leukocytes is gN ’
2:4 days1 (Deubelbeiss et al., 1975). Novak and
Necas (1994) give the daily leukocyte production as 2:4 109 cells kg1 day1 . This gives N ’ 0:5
109 cells kg1 day1 for humans. We have used a range
of N ’ 0:35–0:7 109 cells kg1 day. Lebowitz and
Rubinow (1969) estimate a maturation time for neutrophils of tN ¼ 3–10 days, following the analysis of
Hearn et al. (1998) we take tN ¼ 3:5 days for the
leukocyte compartment.
The amplification parameter in the leukocyte line, AN ,
has been estimated by Mackey (2000) as 300,000 based
on the data in Cheshier et al. (1999), and as 171,000
based on the data of Abkowitz et al. (2000). The
previous model of Bernard et al. (2003) gives a range of
0–100,000 based on Novak and Necas (1994). We have
taken a value of AN ¼ 75; 200, which is within this
range. We will adjust the units of N so that the
numerical value of AN we use in the steady-state is 75;
the units of N are 109 cells kg1 body mass while the
units of Q (the quiescent stem cells) are 106 cells kg1 .
The Hill function parameters used in our model
are similar to those given in Bernard et al. (2003),
where the range of the parameter f 0 was given to be
f 0 ¼ 0:4–1:5 days1 based on experiments in Sachs and
Lotem (1994) and Ward et al. (1999) on the effects of
G-CSF administration on cell production. Bernard et al.
estimate y1 ¼ 0:36 108 cells kg1 from data given in
Ward et al. (1999); Lotem and Sachs (1998); Akbarzadeh et al. (2002), and n ¼ 1. In our model, we compute
kN ¼ kN ðN Þ ¼
gN N
AN Q
from Eq. (2) evaluated at steady-state conditions.
Having found kN , we compute f 0
f 0 ¼ kN
y1 þ N
¼ 0:4.
y1
2.2.3. The erythrocyte compartment
Mahaffy et al. (1998a) have already estimated most of
the required parameters. The mean (steady state)
erythrocyte number is 3:5 1011 cells kg1 body weight.
The maturation time tRM is approximately 6 days, and
the total lifespan, corresponding to the time spent in the
lower compartment in our model, tsum , is 120 days. The
reticulocyte lifespan tret is 2.8 days (Beutler et al., 1995).
ARTICLE IN PRESS
123
C. Colijn, M.C. Mackey / Journal of Theoretical Biology 237 (2005) 117–132
The loss rate from the erythrocyte compartment was
estimated to be gR ¼ 0:001 days1 . Based on a comparison with the data presented in Erslev (1991) and
Mahaffy et al. (1998a) estimated the Hill function
parameters to be m ¼ 6:96 and K r ¼ 0:0382.
We used the same approach as in the leukocyte
compartment to estimate kR based on the steady-state
values, and k̄r from kR
kR ¼
gR R
AR Q ð1 egR
tRS Þ
and
k̄r ¼ kR ð1 þ K R Rm Þ.
In these calculations we use AR ¼ 563; 000 as the
amplification in the erythrocyte line. Beutler et al.
(1995) estimated 10–12 divisions between the proerythroblast stage and the mature red blood cells, while
Novak and Necas (1994) estimate 9 doubling stages
between the stem cells and the proerythroblasts, for a
total of 19–21 divisions. Our amplification factor is thus
approximately 219 .
2.2.4. The platelet compartment
For platelets, Santillan et al. (2000) have estimated
many of the relevant parameters. Thus, the mean
platelet count is P ¼ 2:5 108 cells mL1 blood. Using
the fact that a 70 kg adult has 6 L of blood, we find
P ¼ 2:14 1010 cells kg1 body mass. By fitting the
TPO concentration versus the platelet count data given
in Kuter (1996), Santillan et al. (2000) estimate the Hill
function parameters to be K P ¼ 31:18 in units of P ,
and r ¼ 1:29. We convert K P to kg cell1 (as we
are not going to work in units of P ) so that
K P ¼ 11:66 ð1010 cells kg1 Þ1 . However, due to the
range of observed steady-state values of P, P 2
ð1:4; 4Þ 1010 cells kg1 body mass, we require some
flexibility in P , which is implemented in our model by
allowing K P to change: K P 2 ð3; 13Þ 1010 cells kg1
body mass. Finally, Santillan et al. (2000) estimated
that gP ¼ 0:15, tPM ¼ 7 days and tPS ¼ 9:5 days.
The estimation of kP in the platelet case has been
done somewhat differently than in the erythrocyte and
leukocyte compartments, because it is necessary to set
kP to ensure that a non-zero steady state will exist in the
model. In other words, if the efflux from the resting
phase of the stem cell compartment is too large, the
small influx to the resting-phase stem cell compartment
from the proliferating phase will be insufficient and
the stem cells numbers will decrease exponentially to
zero. For this reason, we ensure that (with reference to
Eq. (1)),
ðkN þ kR þ kP þ b Þ þ 2egS tS b ¼ 0
(16)
for the values of N , R and P found from the
literature. k̄p is found in the same manner as k̄r , and we
use a value of AP ¼ 282; 000 for the platelet amplification factor. Beutler et al. (1995) reports that approximately 35; 000 platelets are produced per mL of blood
per day, which, translated into the context of our model,
would mean that AP times the steady-state flux out of
the stem cell compartment should be approximately
this amount, or 2:57 109 cells kg1 day1 . The steadystate flux out of the stem cell compartment is kP Q .
We can, therefore, solve for AP kP 2500. Since it
turns out from Eq. (16) that kP is on the order of 102 ,
this is consistent with our amplification factor. A
summary of the parameters used in the model is given
in Table 2.
Table 2
Parameters used for the steady state
Parameter name
Value used
Stem cell compartment
1.1
Q
gS
0.1
2.8
tS
k0
3.0
0.5
y2
s
4
Unit
Sources
106 cells kg1
Days1
Days
Days1
106 cells kg1
(none)
1
1
1,2
1
1
1
Leukocyte compartment
3.55–7
N
gN
2.4
3.5
tN
AN
75,200
(75.2)
f0
0.40
0.36
y1
n
1
108 cells kg1
Days1
Days
(none)
2,3
1,4,5
1
1,3
Days1
108 cells kg1
(none)
(calculated)
1
1
Erythrocyte compartment
3.5
R
gR
0.001
6
tRM
tsum
120
tret
2.8
AR
563,000
k̄r
1.1
0.0382
Kr
m
6.96
1011 cells kg1
Days1
Days
Days
Days
(none)
Days1
ð1011 cells kg1 Þm
(none)
6
6
6
6
3
3,7
(calculated)
6
6
Platelet compartment
P
2.14
gP
0.15
7
tPM
tPS
9.5
AP
282,000
1.17
k̄p
11.66
Kp
r
1.29
1010 cells kg1
Days1
Days
Days
(none)
Days1
ð1010 cells kg1 Þr
(none)
8
8
8
8
3
(calculated)
8
8
Sources: 1 ¼ Bernard et al. (2003), 2 ¼Abkowitz et al. (1988),
3 ¼Beutler et al. (1995), 4 ¼Deubelbeiss et al. (1975), 5 ¼Haurie and
Mackey (2000), 6 ¼Mahaffy et al. (1998b), 7 ¼Novak and Necas
(1994), 8 ¼Santillan et al. (2000).
ARTICLE IN PRESS
124
C. Colijn, M.C. Mackey / Journal of Theoretical Biology 237 (2005) 117–132
3. Data
We have analysed data taken from published studies
of periodic CML. These data were previously analysed
for significant periodicity using Lomb periodogram
(Lomb, 1976) techniques by Fortin and Mackey
(1999). Each primary study presented time series of
patient leukocyte counts, and some also provided
platelet and reticulocyte data. In all but two of the
studies the patient was untreated.
Fortin and Mackey (1999) digitized the published
data, converting the result to PostScript format using
PhotoShop 4.0. The times and values of each data point
were then digitally extracted. Upon Lomb periodogram
analysis, Fortin and Mackey (1999) found 9 sets of data
showing significant periodicity in the leukocytes and
platelets (at significance levels pp0:05, in addition to
several cases in which the platelets were reported to be
oscillating, but the platelet data were not published. We
have analysed the 9 data sets in which leukocytes and
platelets were oscillating; in two of these, oscillations in
the reticulocytes were observed as well. We have also
analysed two data sets for which only leukocyte data
were available. These 11 data sets are the data which we
are interested in simulating with our model.
The original studies in which the data are published
are: Kennedy (1970), Rodriguez and Lutcher (1976),
Gatti et al. (1973), Vodopick et al. (1972), Yamauchi
and Ide (1992) and Umemura et al. (1986), Morley et al.
(1967), Iizuka et al. (1984), Chikkappa et al. (1976) and
Delobel et al. (1973). In the study by Kennedy (1970),
the patient was undergoing constant hydroxyurea
treatment; because the dosage was constant it is not
believed that the treatment initiated the cyclicity. The
patient described in Rodriguez and Lutcher (1976) was
receiving bulsafan treatment; however, there was evidence of cycling before treatment began. None of the
other patients were undergoing treatment. Only leukocyte data are given in Delobel et al. (1973) and Gatti
et al. (1973), while platelet data are given in all the other
cases; only Chikkappa et al. (1976) and Iizuka et al.
(1984) give reticulocyte data. There is considerable
variation not only in the periods, which range from 40
to 80 days, but also in the leukocyte means, for which
the range spans a factor of 6, between 20 109 and
120 109 cells L1 .
4. Simulation and fitting
There are several possibilities for the simulation of
PCML in the context of this model. It has been
suggested, for example, that CML originates in the
HSC compartment, both because the Philadelphia
chromosome is found in is all of the hematopoietic
lineages, as mentioned in Section 1, and because in
PCML all cell lines oscillate with the same period. It is
of interest to discover to what extent the observed
relationship between the cell lines is duplicated in the
model. The periods in PCML are also of interest, being
between 40 and 80 days. This is significantly longer than
the periods in other oscillating hematopoietic diseases
like CN, and is two orders of magnitude longer than the
duration of the proliferating phase of the cell cycle in the
stem cells.
A variety of approaches to simulating PCML, based
on existing notions of the mechanisms of the disease,
were initially tried. For example, based on the hypothesis that oscillations are caused by changes in the
dynamics of the HSC, we changed the apoptosis rate gs
in the stem cell compartment to determine whether this
might induce oscillations like those seen in PCML.
However, with the parameters as estimated in Section
2.2, the oscillations generated had periods in the 20 day
range, which is well below the entire observed range in
PCML. In addition, the leukocytes did not oscillate
significantly above the steady state in any of these
simulations in contrast to the clinical data.
In PCML there is a large proliferation of leukocytes,
so we simulated this excessive proliferation by increasing
the parameter AN from its steady-state value of
approximately 75 to much higher values of 1000–5000.
However, this also did not result in leukocyte numbers
at the observed levels, and in general did not lead to a
bifurcation in the stability of the steady state, and
sustained oscillations. Other attempts to simulate
PCML based on intuition were not successful in
duplicating the observed behavior of the system.
However, it must be recognized that the parameter
space for this model is large, and intuitive explorations
are capable of describing the behavior in only a tiny
subset of the parameter space.
Thus, some notion of where in the parameter space to
begin the simulations is essential. In Pujo-Menjouet
et al. (2001), some exploration of long-period oscillations in a G 0 model of HSCs has been carried out. In
fact, Eq. (1) reduces to the equation used in PujoMenjouet et al. (2001) in the case that all the
differentiation rates k are constant. Pujo-Menjouet et
al. (2001) examined how to create long-period oscillations in the model, both at smaller values of s (the
exponent in the Hill function bðQÞ), and as s ! 1.
Their results (for s ¼ 4) provided a starting point at
which our model generated long-period oscillations.
It is also necessary to specify the initial history of the
variables, since there are delays in the system. In our
simulations, the histories over times t 2 ½240; 120
were set to the healthy, default values. Then, while
t 2 ½120; 0, the system was integrated, allowing
transient behavior to disappear; in most cases, since of
course the parameters were significantly different from
the steady-state (healthy) parameters, oscillations
ARTICLE IN PRESS
C. Colijn, M.C. Mackey / Journal of Theoretical Biology 237 (2005) 117–132
occurred during this time. Simulations were compared
to observed data starting at t ¼ 0. Thus, the histories
immediately prior to comparison with the data are not
constant functions, but vary depending on the parameter choices for the particular simulation.
We use and compare two distinct approaches to the
fitting of the model to the observed data. In the first
approach, we have used B. Ermentrout’s implementation of the Marquardt–Levenberg method, described in
Press et al. (1992), which is included with the software
xppaut. The Marquardt–Levenberg method minimizes
the function
w2 ¼
N
X
ðys yi Þ2
,
s2i
i¼1
(17)
where yi are the observed data points, ys are the
simulated data points, si are the estimated standard
deviations of the noise in the observed data points, and
N is the total number of points available. However, we
do not have access to values of si for each data point,
and have had to assume that
si ¼ s ¼ constant
(18)
over each data set. In our case, xppaut sets s2 to be the
standard deviation of the data for the leukocytes,
platelets and reticulocytes separately, to provide scaling
information to the algorithm.
Leukocytes
Data
S¼
N
X
ðys yi Þ2
for each data type, i.e. for the leukocytes, platelets and
reticulocytes separately.
The primary advantage of this method of fitting is
that it quite rapidly converges to a nearby minimum in
w2 , using a variable step size in the parameter adjustment
to aid convergence. However, it has the disadvantage
that in a parameter space in which there are many local
‘energy’ (w2 ) minima, the algorithm will converge to a
local minimum and will not be able to escape that
minimum even if there is a global minimum elsewhere in
parameter space.
Because of the problem of multiple local minima, it
was necessary to make every effort to begin the
Marquardt–Levenberg convergence algorithm at a point
in parameter space from which it was likely that a ‘good’
minimum would be reached. This process was carried
out by hand, using our putative understanding of the
possible biological processes involved in PCML as well
as experience with generating oscillations in the model.
For example, the parameter AN was set higher than the
steady state, while tS , k0 and gS were set within estimated
ranges to generate long-period oscillations. The other
parameters were initiated at their steady-state values.
Full Simulation
25
20
20
20
15
15
15
10
10
10
5
5
5
0
200
Data
0
0
200
Full Simulation
25
0
20
20
15
15
15
10
10
10
5
5
5
0
200
0
Sampled Simulation
0
200
Sampled Simulation
25
20
0
(19)
i¼1
25
25
Platelets
In this case, minimizing w2 is simply the same as
minimizing the sum of squares
25
0
125
0
0
200
0
200
Fig. 2. An example of the results of the Marquardt–Levenberg fitting to the Vodopick et al. (1972) data, Case 2. Leukocytes are in units of 109 kg1 ,
while platelets are in units of 1010 kg1 . In the left-hand panels are the observed data; the centre panels shows the full simulation and the right-hand
panel plots show the data and the simulation sub-sampled at the observed data times reported by Vodopick et al. (1972).
ARTICLE IN PRESS
126
C. Colijn, M.C. Mackey / Journal of Theoretical Biology 237 (2005) 117–132
Leukocytes
Data
20
20
20
10
10
10
0
Platelets
Sampled Simulation
Full Simulation
0
200
400
0
0
0
200
400
15
15
15
10
10
10
5
5
5
0
0
0
200
400
200
400
0
200
400
0
200
400
0
0
200
400
0.5
0.5
Reticulocytes
0.5
0
0
0
200
400
0
0
200
400
0
Fig. 3. An example of the results of the Marquardt–Levenberg fitting to the Iizuka et al. (1984) data. Leukocytes are in units of 109 kg1 , while
platelets are in units of 1010 kg1 . In the left-hand panels are the observed data; the centre panels shows the full simulation and the right-hand panel
plots show the data and the simulation sub-sampled at the observed data times reported by Iizuka et al. (1984).
Table 3
Parameter estimates for the 11 patients of this study based on the Marquardt–Levenberg method
Default
Iizuka
Chikkappa
Delobel
Gatti
Kennedy
Morley
Rodriquez
Umemura
Vodopick (1)
Vodopick (2)
Yamauchi
AN
f0
AP
kP
gS
k0
75.00
0.40
28.00
1.17
0.18
3.00
167.7
277.5
283.6
169.0
190.1
291.7
335.9
153.3
236.7
327.1
138.8
(1.23)
(1.19)
(2.87)
(0.25)
(0.31)
(10.08)
(19.52)
(33.11)
(0.04)
(0.04)
(64.16)
5.81
5.42
6.70
5.81
3.50
30.09
3.54
1.39
5.74
9.61
1.83
(1.17)
(0.65)
(0.99)
(0.10)
(0.13)
(9.41)
(9.09)
(16.55)
(0.01)
(0.11)
(109.56)
39.17
59.44
28.14
28.21
13.96
30.14
1.57
16.52
45.56
65.50
17.94
(0.00)
(1.06)
(0.00)
(0.00)
(51.80)
(0.59)
(854.00)
(48.31)
(0.63)
(3.38)
(47.39)
0.45
0.55
0.44
0.44
0.32
0.56
0.06
1.46
0.83
0.93
0.92
(0.00)
(0.51)
(0.00)
(0.00)
(24.71)
(0.26)
(280.39)
(6.02)
(0.20)
(0.67)
(29.40)
0.18
0.18
0.18
0.19
0.19
0.13
0.18
0.19
0.18
0.18
0.19
(0.02)
(0.02)
(0.02)
(0.02)
(0.02)
(0.02)
(0.02)
(0.01)
(0.02)
(0.02)
(0.01)
3.01
3.30
3.01
3.04
2.30
4.17
1.54
2.47
2.93
2.51
2.03
(0.99)
(1.57)
(0.52)
(0.00)
(0.00)
(0.03)
(7.83)
(10.98)
(0.04)
(0.41)
(14.56)
The top line of the table gives the default values from Table 2 for comparison. Error estimates, in percent, are shown in brackets.
Sample plots showing the data and the fit are given in
Figs. 2 and 3. As shown in the plots, there are longperiod oscillations forming an envelope around much
higher-frequency oscillations, particularly in the leukocytes. This was a typical feature of most of our
simulations, and has also occurred in previous models
based on the G 0 description of the stem cells (PujoMenjouet et al., 2001). It is therefore not an artifact
of particular parameter sets chosen by the fitting
algorithms.
It should be noted that the data are quite sparsely
sampled, over significant time periods. For example, in
the Vodopick et al. (1972) data, the first few points are
at t ¼ 10; 40; 54 . . . days, where near the end of the data
set there are points at every 2 or 3 days. The sparse
sampling means that over wide time ranges, it is not
possible for the fitting algorithm to distinguish between
simulations which contain higher-frequency oscillations
and those which do not. In addition, there are segments
of the observed data which do seem to show rapid
ARTICLE IN PRESS
C. Colijn, M.C. Mackey / Journal of Theoretical Biology 237 (2005) 117–132
changes; see for example Iizuka et al. (1984) and Gatti
et al. (1973).
The parameters found using the Marquardt–Levenberg algorithm are given in Table 3. In this table, the
values in parentheses are the errors in the estimates,
given as a percentage of the corresponding parameter
value. These estimates are based on the covariance
matrices computed by the fit procedure.
In these results, several trends of importance emerge.
First, the values of the amplification parameter AN in
the leukocyte line are all well above the steady-state
value of 75. The rate of differentiation into the leukocyte
line, f 0 , is also significantly greater than the steady-state
value, implying that in PCML not only is there more
amplification of the cellular precursors entering the
leukocyte line, but that there are increased numbers of
stem cells entering the leukocyte pathway. Both of these
conclusions drawn from the model fitting procedure are
consistent with clinical observations, giving us added
confidence in the fitting results. It was found in
simulations that changing the parameter y2 , part of
the Hill function regulating the rate of proliferation of
the quiescent stem cells, does not significantly improve
the fit. y2 has not been included in the table, nor in
subsequent fitting procedures. However, k0 , which scales
the overall proliferation rate of the stem cells, has varied
between 1.5 and 4 in these results, consistent with the
(Bernard et al., 2003) range of k0 of 2.0–10.0.
The parameter estimates for gS with the Marquardt
–Levenberg method require some discussion, as in some
cases the system was so sensitive to small changes in gS
that either convergence was apparently impossible, or
given convergence the estimated error was so small that
it seemed unreasonable. Where gS could not be included
in the fitting procedure, it was left fixed at a value near
the default value, with the requirement that the fitting
procedure gave reasonable convergence in the other
parameters. It is for this reason that the cited errors in
Table 3 for gS are very small. Also for this reason, it is
not meaningful to draw conclusions about the relationship between the results for gS and the apoptosis in the
stem cell compartment in PCML. This limitation does
not apply, however, to the second fitting approach,
discussed below.
In the second parameter estimation scheme, we
implemented a simulated annealing procedure. Simulated annealing is an approach to optimization which
simulates physical cooling of metals. Originally derived
from computer simulation of physical equilibrium
(Metropolis et al., 1953), the algorithm explores the
parameter space looking for a minimum in an ‘energy
function’, which in this case is the sum of squares as
given in Eq. (19). However, unlike other optimization
procedures, in simulated annealing the current parameter set may be altered to one which gives a higher
energy, when one yielding a lower energy cannot be
127
found. In this way, the system is perturbed out of local
minima. The cooling, or annealing, is done by gradually
decreasing the likelihood that such an upward move will
be accepted. Simulated annealing is known to be highly
advantageous when the energy function contains many
local minima.
Our energy function is given by
vffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
uM s
uX ðL Li Þ2 ðPs Pi Þ2
i
þ i
E¼t
¯2
L
P¯2
i¼1
s
ðN̄ N̄Þ2 ðP̄s P̄Þ2
þd
þ
Þ
2
2
N̄
P̄
ðvarðN s Þ varðNÞÞ2 ðvarðPs Þ varðPÞÞ2
þ
.
þd
varðNÞ2
varðPÞ2
ð20Þ
Here, N and P refer to leukocytes and platelets, while
the superscript s indicates simulation, and the lack of a
superscript indicates observed data. The bars indicate
that the mean has been taken, and ‘var’ refers to the
variance. M is the number of data points available.
In the cases where platelet data are not available, the
terms involving platelets are simply left out. Where
reticulocyte data are available, the energy function is
vffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
uM s
uX ðN Li Þ2 ðPs Pi Þ2 ðLs Li Þ2
i
E¼t
þ i 2
þ i 2
2
N̄
P̄
L̄
i¼1
s
ðN̄ N̄Þ2 ðP̄s P̄Þ2
ðL̄s L̄Þ2
þ
Þþ
Þ
þd
2
2
2
N̄
P̄
L̄
ðvarðN s Þ varðNÞÞ2 ðvarðPs Þ varðPÞÞ2
þd
þ
varðNÞ2
varðPÞ2
þ
ðvarðLs Þ varðLÞÞ2
,
varðLÞ2
ð21Þ
where the notation is as it is in Eq. (20), and L refers to
the reticulocytes.
This energy function is simpler than it may appear.
The first and dominant term is the usual sum of squares,
with the leukocytes and platelets each normalized by
their means to prevent the fit being dominated by one of
them. (In other words, the presence of N̄, P̄ and L̄ in
Eqs. (20) and (21) provides scaling information.) The
square root deforms this function monotonically,
making the energy landscape less steep. Such monotonic
deformations are common in simulated annealing
approaches. The remaining terms involving the means
and variances of the leukocytes and platelets are scaled
by a small parameter d; these terms encourage oscillatory solutions (recall that all of our data have been
previously tested for periodicity using the Lomb
algorithm (Fortin and Mackey, 1999)). Without these
terms, non-oscillatory solutions would frequently
emerge from the annealing process, because a constant
ARTICLE IN PRESS
128
C. Colijn, M.C. Mackey / Journal of Theoretical Biology 237 (2005) 117–132
solution can have a lower sum-of-squares energy
function than an out-of-phase but oscillatory solution,
or an oscillatory solution at a slightly different
frequency Adding these terms to the energy function
successfully reduced the likelihood that the simulations
would converge to a steady-state solution.
The details of our simulated annealing procedure are
as follows. We use the Metropolis acceptance rule
(Metropolis et al., 1953) for determining whether a
proposed perturbation of the parameters will be
accepted, namely that it is accepted if the move will
decrease the energy. If none of the moves tested decrease
the energy, then an uphill move is accepted with
probability P ¼ eDE=T , where T is the ‘‘temperature’’.
Thus, as T decreases, the probability that an uphill move
will be accepted decreases. In determining how and
when to change the temperature, we have used a
geometric cooling schedule, in which the temperature
is decreased according to the rule
T n ¼ T 0 an ,
(22)
where a 2 ð0:99520:999Þ. This is done after the system
undergoes a random walk of a given length, where the
moves in the random walk are generated by perturbations of the relevant parameters and selected by the
Metropolis algorithm. The initial temperature T 0 is
chosen using the criterion that a given fraction (usually
half) of the attempted uphill moves will be accepted in
the initial random walk. The framework for our
program is due to Salamon et al. (2002), which can be
consulted for a more detailed discussion of simulated
annealing.
We have applied this approach to the PCML data,
comparing the simulations for leukocytes and platelets,
as well as reticulocytes where applicable. The results of
the parameter estimates, along with errors in percentages, are given in Table 4. In terms of the qualitative
features of the simulations, the high-frequency oscilla-
tions observed in the Marquardt–Levenberg fits appeared again in the simulated annealing fits, which is not
surprising as the system has no way of selecting for the
removal of these high-frequency oscillations with the
sparsely sampled data available.
Figs. 4 and 5 show examples of the simulated
annealing output, both with fine sampling (left-hand
plots) and with sampling at the same times as the
observed data (right-hand plots). Note that the highfrequency oscillations are not visible at the lower
sampling rate corresponding to the rate at which the
clinical data were collected.
As in the results for the Marquardt–Levenberg
procedure, the most prominent result is the high overall
rate of amplification in the leukocyte line. In some cases
these are an order of magnitude above the default value
of 75, though in those cases the errors are typically quite
high as well. Here, error estimation was done by finding
how far from the estimated parameter one had to go for
the energy function to increase by 10 percent. This value
is based on the observed similarity of results within this
range of energy values.
In the simulated annealing results, the values of f 0
range widely above the default values as they do for the
Marquardt–Levenberg results. In both simulations there
is a wide range of values of the parameter AP , which is
necessary if the simulations are to match the platelet
data. The rate of apoptosis in the stem cell compartment, gS , is usually found to be around the default range
of 0.16–0.2, but occasionally was altered by the
annealing procedure to a much lower value. This
occurred in the fits to the data of Chikkappa et al.
(1976) and Yamauchi and Ide (1992), and it is
interesting to note that in these cases f 0 was closer to
its default value of 0.4. Increasing f 0 and AN and
perhaps also decreasing gS seem to be ways that the
model can produce long-period oscillations at the
leukocyte levels seen in PCML. Physiologically, this is
Table 4
Parameter estimates for the 11 patients of this study based on the simulated annealing method
Default
Iizuka
Chikkappa
Delobel
Gatti
Kennedy
Morley
Rodriquez
Umemura
Vodopick (1)
Vodopick (2)
Yamauchi
AN
f0
AP
kP
gS
k0
75.00
0.40
28.00
1.17
0.18
3.00
423.8
314.4
187.6
251.3
124.5
763.0
388.6
68.8
316.3
359.9
532.4
(4.51)
(39.35)
(4.74)
(6.87)
(9.32)
(2.60)
(2.59)
(0.81)
(0.68)
(19.6)
(42.0)
2.22
12.74
19.91
8.44
1.98
20.48
5.57
3.76
2.75
9.07
0.53
(12.5)
(6.97)
(0.77)
(3.60)
(4.89)
(2.03)
(12.6)
(0.5)
(2.60)
(8.30)
(27.6)
24.30
4.21
34.16
37.57
5.57
26.88
8.48
13.85
55.97
19.07
8.94
(10.00)
(12.39)
(16.85)
(7.39)
(12.90)
(19.9)
(13.8)
(2.60)
(1.15)
(6.21)
(4.92)
1.07
4.55
0.83
0.53
3.53
0.75
0.05
1.74
1.58
5.06
1.93
(10.4)
(20.15)
(4.99)
(5.62)
(11.34)
(2.27)
(28.1)
(1.3)
(5.00)
(13.2)
(5.6)
0.17
0.12
0.17
0.15
0.13
0.18
0.18
0.17
0.16
0.14
0.04
(2.42)
(5.39)
(0.23)
(5.00)
(3.20)
(0.08)
(7.38)
(0.04)
(2.50)
(5.08)
(19.38)
3.09
2.81
2.89
1.02
0.98
3.77
1.63
2.32
3.88
1.30
1.05
The top line of the table gives the default values from Table 2 for comparison. Error estimates, in percent, are shown in brackets.
(7.81)
(13.9)
(0.47)
(8.16)
(7.98)
(4.95)
(12.2)
(0.2)
(1.9)
(8.4)
(14.3)
ARTICLE IN PRESS
129
C. Colijn, M.C. Mackey / Journal of Theoretical Biology 237 (2005) 117–132
Leukocytes
Full Simulation
Data
25
25
20
20
20
15
15
15
10
10
10
5
5
5
0
0
0
200
0
0
Data
25
Platelets
Sampled Simulation
25
200
0
Sampled Simulation
Full Simulation
25
25
20
20
20
15
15
15
10
10
10
5
5
5
0
0
0
200
200
0
0
200
0
200
Fig. 4. An example of the results of the simulated annealing fitting to the Vodopick et al. (1972) data, Case 2. Leukocytes are in units of 109 kg1 ,
while platelets are in units of 1010 kg1 . In the left-hand panels are the observed data; the centre panels shows the full simulation and the right-hand
panel plots show the data and the simulation sub-sampled at the observed data times reported by Vodopick et al. (1972).
Leukocytes
Data
20
20
20
10
10
10
0
0
0
Platelets
Sampled Simulation
Full Simulation
200
400
0
0
200
400
15
15
15
10
10
10
5
5
5
0
0
0
200
400
200
400
0
200
400
0
200
400
0
0
200
400
0.5
0.5
Reticulocytes
0.5
0
0
0
0
200
400
0
0
200
400
Fig. 5. An example of the results of the simulated annealing fitting to the Iizuka et al. (1984) patient data. Leukocytes are in units of 109 kg1 , while
platelets are in units of 1010 kg1 and reticulocytes are in units of 1011 kg1 . On the left hand side are the observed clinical data; the centre panels
show the full simulation and the right-hand plots show the data and the simulation sub-sampled at the observed data times reported by Iizuka et al.
(1984).
ARTICLE IN PRESS
130
C. Colijn, M.C. Mackey / Journal of Theoretical Biology 237 (2005) 117–132
consistent with excess proliferation in the leukocyte line
as well at the stem cell level. Because this model does not
explicitly represent each stage of leukocyte development,
perhaps a decrease in gS is as close as the system can
come to representing excess proliferation of stem cells
that are differentiating into the leukocyte line.
Our simulations also allow us to comment on the
likely origin of the oscillations observed in PCML.
Using the parameter sets presented in Tables 3 and 4, we
ran simulations in a model system containing only the
stem cells and leukocytes; in other words, the coupling
to the platelet and erythrocyte compartments was
removed. In most cases, this ‘‘decoupled’’ system still
oscillates, implying that the parameter changes in the
stem cell and leukocyte compartments are sufficient to
destabilize the steady state and lead to oscillations. In
the remaining (non-oscillating) cases, the decoupled
system was close, in parameter space, to one that did
oscillate. (These nearby parameter sets were found either
by examining the results of the simulated annealing
procedure that generated the parameter sets of Table 4,
or by running the annealing procedure with the
decoupled model beginning from the parameter sets in
Table 4.)
In addition, when the leukocyte compartment is then
removed, leaving only the stem cell compartment in the
model, the oscillations disappear, and the stem cell
population decreases to zero. Thus, we feel that we can
assert with some certainty that the oscillatory nature of
PCML is due to a bifurcation in the combined dynamics
of the regulation of the HSC and the neutrophil control.
The nature of this bifurcation will be studied in a future,
more mathematically oriented, communication.
Overall, the quality of the simulated annealing fits is
notably better than that of the Marquardt–Levenberg
fits, almost certainly because less prior knowledge (of
where to begin the fit) is required, and the simulated
annealing approach is less likely to converge to a local
minimum. In order to compare the relative quality of the
fits from the two procedures, we computed a w2 -like
function for all the fits; this function was the same as the
energy function defined in Eqs. (20) and (21), except that
the terms involving the means and variances of the
simulation and data (those terms that were scaled by d in
the energy function) were omitted.
Thus, we computed
vffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
uM s
uX ðN N i Þ2 ðPs Pi Þ2 ðLs Li Þ2
i
w¼t
(23)
þ i 2
þ i 2
2
N̄
P̄
L̄
i¼1
(leaving out the platelet and reticulocyte terms when
data were not available). This w function is not the same
as the usual w2 ; notably, the means of the data are in our
function in place of the standard deviations usually used
in computing w2 . However, since there are indications
that fluctuations of cell numbers are not normally
distributed even in normal circumstances (Perazzo et al.,
2000), there is no significant advantage in using the
usual w2 function for comparison. There is an advantage
in using the mean values, as we have done, for this
ensures that the platelets and the neutrophils are
‘weighted’ equally. Using the function given in
Eq. (23), we find that the simulated annealing fits have
lower w values by an order of magnitude, on average,
than the Marquardt–Levenberg fit results. This quantitatively confirms the observation that the simulations
generated by the simulated annealing fit parameters
‘look better’ when compared to the data.
5. Discussion and conclusions
PCML is a strange cycling disease of the hematopoietic system in which oscillating levels of circulating
leukocytes, platelets and/or reticulocytes are observed
(Fortin and Mackey, 1999; Haurie et al., 1998).
Typically it is observed that all of these three differentiated cell types have the same oscillation period, but
that the relation of the oscillation mean and amplitude
to the normal levels is variable. Given the common
appearance of the abnormal Philadelphia chromosome
in all of the nucleated progeny of the HSCs, the simplest
conclusion is that CML, and its periodic variant, arise
from derangements partially involving the dynamics of
the stem cells.
Here, we have synthesized several previous mathematical models of hematopoietic stem cell dynamics
(Mackey, 1978, 1979a, 2000; Pujo-Menjouet et al.,
2001), and models for the regulation of neutrophils
(Hearn et al., 1998; Haurie and Mackey, 2000; Bernard
et al., 2003), platelets (Bélair and Mackey, 1987;
Santillan et al., 2000) and erythrocytes (Mackey,
1979b; Bélair et al., 1995; Mahaffy et al., 1998a) into a
single model for the regulation of the hematopoietic
system. Based on estimates of parameters for a typical
normal human, we have systematically explored the
changes in some of these parameters necessary to
account for the quantitative data on leukocyte, platelet
and reticulocyte cycling in 11 patients with PCML.
We have used two different fitting procedures (the
Marquardt–Levenberg procedure as well as simulated
annealing), and there is an interesting and encouraging
concordance between the results of both. In the most
general terms, both lead to qualitative and quantitative
agreement with the published data on PCML in
reproducing the period, amplitudes and mean values
of the oscillating cell types as well as the relative phase
differences between them. It is significant that the
present model is capable of duplicating the overall
features of the coupled oscillations in several cell lines.
The platelet oscillations in the fitted simulations,
particularly with the simulated annealing method,
ARTICLE IN PRESS
C. Colijn, M.C. Mackey / Journal of Theoretical Biology 237 (2005) 117–132
matched the observed data fairly well, including the
relative phase. Where reticulocyte data were available,
the oscillations were also matched. This indicates that
the model is capable of generating the observed coupling
between the cell lines.
Note that there is often a high-frequency oscillation
on top of these long time periods, but there is nothing in
the available data that would rule out the possibility of
high-frequency oscillations in cell numbers. However, it
is likely that if the model included distributions of
maturation delay times, rather than single discrete
delays, some smoothing of this high-frequency output
might occur.
Our results indicate that the oscillatory nature of
PCML is probably generated through a bifurcation in
the dynamics of the coupled HSC compartment and the
regulation of differentiated leukocytes. Based on the
simulations, the critical model parameter changes
required to simulate the periodic chronic myelogenous
leukemia patient data are the amplification in the
leukocyte line (AN ), the differentiation rate from the
stem cell compartment into the leukocyte line (f 0 ), and
the rate of apoptosis in the stem cell compartment (gS ).
Our model system is also particularly sensitive to
changes in gS , suggesting that changes in the numbers
of proliferating stem cells may be important in generating PCML. However, there was no indication that the
rate of re-entry from the quiescent stem cell compartment to the proliferating phase stem cells was involved.
The platelet parameters seem to be of secondary
importance, and changes in these seem to merely adjust
levels of mean platelet levels and amplitude of the
excursions from the mean.
Acknowledgements
This work was supported by MITACS (Canada) and
the Natural Sciences and Engineering Research Council
of Canada.
References
Abkowitz, J., Golinelli, D., Harrison, D., Guttorp, P., 2000. The in
vivo kinetics of murine hemopoietic stem cells. Blood 96,
3399–3405.
Abkowitz, J.L., Holly, R.D., Hammond, W.P., 1988. Cyclic hematopoiesis in dogs: studies of erythroid burst forming cells confirm an
early stem cell defect. Exp. Hematol. 16, 941–945.
Adamson, J., 1974. The relationship of erythropoietin and iron
metabolism to red blood cell production in humans. Semin. Oncol.
21, 9–15.
Akbarzadeh, S., Golinelli, D., harrison, D., Guttorp, P., 2002.
Tyrosine residues of the granulocyte colony-stimulating factor
receptor transmit proliferation and differentiation signals in murine
bone marrow cells. Blood 99, 879–887.
Bélair, J., Mackey, M., 1987. A model for the regulation of
mammalian platelet. Ann. NY Acad. Sci. 504, 280–282.
131
Bélair, J., Mackey, M., Mahaffy, J., 1995. Age-structured and twodelay models for erythropoiesis. Math. Biosci. 128, 317–346.
Bernard, S., Belair, J., Mackey, M., 2003. Oscillations in cyclical
neutropenia: new evidence based on mathematical modeling.
J. Theor. Biol. 223.
Beutler, E., Lichtman, M.A., Coller, B.S., Kipps, T., 1995. Williams
Hematology. McGraw-Hill, New York.
Boggs, D., Boggs, S., Saxe, D., Gress, L., Canfield, D., 1982.
Hematopoietic stem cells with high proliferative potential: assay
of their concentration in marrow by the frequency and duration of
cure of W/Wv mice. J. Clin. Invest. 70, 242–253.
Cheshier, S., Morrison, S., Liao, X., Weissman, I., 1999. In vivo
proliferation and cell cycle kinetics of long term self-renewing
haematopoietic stem cells. Proc. Natl Acad. Sci. USA 96, 3120–3125.
Chikkappa, G., Borner, A.H.B., Chanana, A.D., Cronkite, E.P., Ohl,
S., Pavelec, M., Robertso, J.S., 1976. Periodic oscillation of blood
leukocytes, platelets, and reticulocytes in a patient with chronic
myelocytic leukemia. Blood 47, 1023–1030.
Delobel, J., Charbord, P., Passa, P., Bernard, J., 1973. Evolution
cyclique spontanée de la leucocytose dans un cas de leucémie
myéloide chronique. Nouv. Rev. franc Hémat. 13, 221–228.
Deubelbeiss, K.A., Dancey, J.T., Harker, L.A., Finch, C.A., 1975.
Neutrophil kinetics in the dog. J. Clin. Invest. 55, 833–839.
Erslev, A., 1991. Erythropoietin titers in health and disease. Semin.
Hematol., 779–791.
Fortin, P., Mackey, M., 1999. Periodic chronic myelogenous leukemia:
Spectral analysis of blood cell counts and etiological implications.
Br. J. Haematol. 104, 336–245.
Fowler, A., Mackey, M., 2002. Relaxation oscillations in a class of
delay differential equations. SIAM J. Appl. Math. 63, 299–323.
Gatti, R.A., Robinson, W.A., Deinard, A.S., Nesbit, M., McCullough,
J.J., Ballow, M., Good, R.A., 1973. Cyclic leukocytosis in chronic
myelogenous leukemia. Blood 41, 771–782.
Grignani, F., 1985. Chronic myelogenous leukemia. Crit. Rev. Oncol.Hematol. 4, 31–66.
Haurie, C., Mackey, M., 2000. Modeling complex neutrophil dynamics
in the grey collie. J. Theor. Biol. 204, 504–519.
Haurie, C., Mackey, M.C., Dale, D.C., 1998. Cyclical neutropenia and
other periodic hematological diseases: a review of mechanisms and
mathematical models. Blood 92, 2629–2640.
Hearn, T., Haurie, C., Mackey, M., 1998. Cyclical neutropenia and the
peripherial control of white blood cell production. J. Theor. Biol
192, 167–181.
Henderson, E.S., Lister, T.A., Greaves, M.F. (eds.), 1996. Leukemia.
Saunders, London.
Iizuka, Y., Horikoshi, A., Sekiya, S., Sawada, U., Ohshima, T.,
Amaki, I., 1984. Periodic fluctuation of leukocytes, platelets and
reticulocytes in a case of chronic myelocytic leukemia: The relation
between leukocyte counts, cfu-c colony formation, csa and cia.
Acta Haematol. Japan 47, 71–79.
Kennedy, B.J., 1970. Cyclic leukocyte oscillations in chronic myelogenous leukemia during hydroxyurea therapy. Blood 35, 751–760.
Kuter, D., 1996. The physiology of platelet production. Stem Cells 14,
88–101.
Lebowitz, J., Rubinow, S., 1969. Grain count distributions in labeled
cell populations. J. Theor. Biol. 23, 99–123.
Lemishka, I.R., Raulet, D.H., Mulligan, R.C., 1986. Developmental
potential and dynamic behavior of hemopoietic stem cells. Cell 45,
917.
Lomb, N.R., 1976. Least-squares frequency analysis of unequally
spaced data. Astrophys. Space Sci. 39, 447–462.
Lotem, J., Sachs, L., 1998. In vivo control of differentiation of myeloid
leukemic cells by recombinant granulocyte–macrophage colonystimulating factor and interleukin 3. Blood 71, 375–382.
Lyons, A.B., 1999. Divided we stand: tracing cell proliferation with carboxy uorescein diacetate syccinimidyl ester. Immunol. Cell Biol. 77.
ARTICLE IN PRESS
132
C. Colijn, M.C. Mackey / Journal of Theoretical Biology 237 (2005) 117–132
Mackey, M.C., 1978. A unified hypothesis for the origin of aplastic
anemia and periodic haematopoiesis. Blood 51, 941–956.
Mackey, M.C., 1979a. Dynamic haematological disorders of stem cell
origin. In: Vassileva-Popova, J.G., Jensen, E.V. (Eds.), Biophysical
and Biochemical Information Transfer in Recognition. Plenum
Publishing Corp, New York, pp. 373–409.
Mackey, M.C., 1979b. Periodic auto-immune hemolytic anemia: an
induced dynamical disease. Bull. Math. Biol. 41, 829–834.
Mackey, M.C., 1996. Mathematical models of hematopoietic cell
replication and control. In: Othmer, H., Adler, F., Lewis, M.,
Dallon, J. (Eds.), The Art of Mathematical Modeling: Case Studies
in Ecology, Physiology and Biofluids. Prentice-Hall, New York,
pp. 149–178.
Mackey, M.C., 2000. Cell kinetic status of haematopoietic stem cells.
Cell Prolif. 34, 71–83.
Mahaffy, J., Belair, J., Mackey, M., 1998a. Hematopoietic model with
moving boundary condition and state dependent delay: applications in erythropoiesis. J. Theor. Biol. 190, 135–146.
Mahaffy, J.M., Bélair, J., Mackey, M., 1998b. Hematopoietic model
with moving boundary condition and state dependent delay.
J. Theor. Biol. 190, 135–146.
Melo, J., 1996. The diversity of bcr–abl fusion proteins and their
relationship to leukemia phenotype. Blood 88, 2375.
Metropolis, N., Rosenbluth, A., Rosenbluth, M., Teller, A., Teller, E.,
1953. Equation of state calculations by fast computing machines.
J. Chem. Phys. 21, 1087–1092.
Micklem, H., Lennon, J., Ansell, J., Gray., R.A., 1987. Numbers and
dispersion of repopulating hematopoietic cell clones in radiation
chimeras as functions of injected cell dose. Exp. Hematol. 15(3),
251–257.
Morley, A.A., Baikie, A., Galton, D., 1967. Cyclic leukocytosis as
evidence for retention of normal homeostatic control in chronic
granulocytic leukaemia. Lancet, 1320–1322.
Novak, J.P., Necas, E., 1994. Proliferation differentiation pathways of
murine haematopoiesis: correlation of lineage fluxes. Cell. Prolif.
27, 597–633.
ODwyer, M., Druker, B.J., Mauro, M., Talpaz, M., Resta, D., Peng,
B., Buchdunger, E., Ford, J., Reese, S.F., Capdeville, R., Sawyers,
C.L., 2000. Sti571: a tyrosine kinase inhibitor for the treatment of
cml. Ann. Oncol. 11, 155.
Ogawa, M., 1993. Differentiation and proliferation of hematopoietic
stem cells. Blood 81, 2844–2853.
Oostendorp, R.A., Audet, J., Eaves, C.J., 1995. High-resolution
tracking of cell division suggests similar cell cycle kinetics of
hematopoietic stem cells stimulated in vitro and in vivo. Blood,
855–862.
Perazzo, C., Fernandez, E., Chialvo, P., 2000. Large scale-invariant
fluctuations in normal blood cell counts: a sign of criticality?
Fractals 8, 279–283.
Press, W., Teukolsky, S., Vetterling, W., Flannery, B., 1992. Numerical
Recipes in C, second ed. Cambridge University, Cambridge.
Price, T.H., Chatta, G.S., Dale, D.C., 1996. Effect of recombinant
granulocyte colony stimulating factor on neutrophil kinetics in
normal young and elderly humans. Blood 88, 335–340.
Pujo-Menjouet, L., Bernard, S., Mackey, M., 2001. Long period
oscillations in a g0 model of hematopoietic stem cells. J. Theor.
Biol. 209.
Ratajczak, M., Ratajczak, J., Marlicz, W., Pletcher, C., Machalinski,
B., Moore, J., Hung, H., Gewirtz, A., 1997. Recombinant human
thrombopoietin (TPO) stimulates erythropoiesis by inhibiting
erythroid progenitor cell apoptosis. Br. J. Haematol. 98, 8–17.
Rodriguez, A.R., Lutcher, C.L., 1976. Marked cyclic leukocytosis
leukopenia in chronic myelogenous leukemia. Am. J. Med. 60,
1041–1047.
Sachs, L., Lotem, J., 1994. The network of hematopoietic cytokines.
Proc. Soc. Exp. Biol. Med. 206, 170–175.
Salamon, P., Sibani, P., Frost, R., 2002. Facts, Conjectures, and
Improvements for Simulated Annealing. Society for Industrial and
Applied Mathematics, Philadelphia.
Santillan, M., Mahaffy, J., Belair, J., Mackey, M., 2000. Regulation of
platelet production: the normal response to perturbation and
cyclical platelet disease. J. Theor. Biol. 206, 585–603.
Silva, M., Grillot, D., Benito, A., Richard, C., Nunez, G., FernandezLuna, J., 1996. Erythropoietin can promote erythroid progenitor
survival by repressing apoptosis through bcl-1 and bcl-2. Blood 88,
1576–1582.
Tanimukai, S., Kimura, T., Sakabe, H., Ohmizono, Y., Kato, T.,
Miyazaki, H., Yamagishi, H., Sonoda, Y., 1997. Recombinant
human c-Mpl ligand (thrombopoietin) not only acts on megakaryocyte progenitors, but also on erythroid and multipotential
progenitors in vitro. Exp. Hematol. 25, 1025–1033.
Umemura, T., Hirata, J., Kaneko, S., Nishimura, J., Motomura, S.,
Kozuru, M., Ibayashi, H., 1986. Periodical appearance of
erythropoietin-independent erythropoiesis in chronic myelogenous
leukemia with cyclic oscillation. Acta Haematol. 76, 230–234.
Vodopick, H., Rupp, E.M., Edwards, C.L., Goswitt, G.A., Beauchamp, J., 1972. Spontaneous cyclic leukocytosis and thrombocytosis in chronic granulocytic leukemia. New Eng. J. Med. 286,
284–290.
Ward, A.C., van Aesch, Y.M., Gits, J., Schelen, A.M., de Koning, J.P.,
van Leeuwen, D., Freedman, M.H., Touw, I.P., 1999. Novel point
mutation in the extracellular domain of the granulocyte colonystimulating factor (G-CSF) receptor and in a case of severe
congenital neutropenia hyporesponsive to G-CSF treatment.
J. Exp. Med. 190, 497–508.
Yamauchi, K., Ide, A., 1992. Spontaneous remission with cyclic
leukocytosis in chronic myelogenous leukemia. Acta Haematol. 88,
136–138.